Cargando…

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐line treatment with abiraterone acetate and prednisone (AA‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boerrigter, Emmy, Benoist, Guillemette E., van Oort, Inge M., Verhaegh, Gerald W., van Hooij, Onno, Groen, Levi, Smit, Frank, Oving, Irma M., de Mol, Pieter, Smilde, Tineke J., Somford, Diederik M., Mehra, Niven, Schalken, Jack A., van Erp, Nielka P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410566/ https://www.ncbi.nlm.nih.gov/pubmed/33650292 http://dx.doi.org/10.1002/1878-0261.12933

Ejemplares similares

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
por: Benoist, Guillemette E., et al.
Publicado: (2020)

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides
por: Luna Velez, Maria V., et al.
Publicado: (2022)

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2014)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
por: Yang, Zhenyu, et al.
Publicado: (2021)

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
por: Chi, Kim N, et al.
Publicado: (2023)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
por: Romero-Laorden, Nuria, et al.
Publicado: (2018)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
por: Purshouse, Karin, et al.
Publicado: (2019)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
por: Liu, Min, et al.
Publicado: (2023)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

A comprehensive resequence analysis of the KLK15–KLK3–KLK2 locus on chromosome 19q13.33
por: Parikh, Hemang, et al.
Publicado: (2009)

Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
por: Ni, Yu-Chao, et al.
Publicado: (2021)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer
por: Rönnau, C. G. H., et al.
Publicado: (2021)

Birth-and-Death of KLK3 and KLK2 in Primates: Evolution Driven by Reproductive Biology
por: Marques, Patrícia Isabel, et al.
Publicado: (2012)

KLK4T2 Is a Hormonally Regulated Transcript from the KLK4 Locus
por: Lundwall, Åke, et al.
Publicado: (2021)

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers
por: van de Merbel, Arjanneke F., et al.
Publicado: (2021)

Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma
por: Rückert, F, et al.
Publicado: (2008)

KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype
por: Kasparek, Petr, et al.
Publicado: (2017)

Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
por: Du, Meijun, et al.
Publicado: (2020)

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2023)

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study
por: Thiery-Vuillemin, Antoine, et al.
Publicado: (2018)

The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2022)

DNA methylation of the KLK8 gene in depression symptomatology
por: Starnawska, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n652v4e8bt1ufvlo8pp1do9ic1